Asthmatic Metered Dose Inhaler

NEW PRODUCT INTRODUCTION

Use the space bar to advance each slide
To participate in final development of the R2 Asthmatic Metered Dose Inhaler
The Product

First *cannabis derived* delivery system and Short-Acting Beta-Agonist (SABA), *metered, multi-dose, rescue inhaler* for treatment of reversible obstructive airway disease and the quick relief of symptoms during asthma and intermittent asthma attacks, and for the prevention of exercise-induced bronchospasm (EIB) in patients 21 years of age and older.

*What is a Metered Dose Inhaler?* *(Rescue Inhaler)*
The Product Opportunity

The patent pending product(s), research and clinical trials are significant to support R2’s proprietary cannabis derivative formulations. Preliminary studies and findings have proven conclusively that the methodology incorporating a proprietary, non-viscous formulation *(Supercritical, CO2 extracted Cannabis Oils)* of phytocannabinoid (cannabis derivatives), including Tetrahydrocannabinol (THC) and other discovered combinations of cannabinoids (CBD, CBN, CBC, CBG’s) derived from various proprietary marijuana strains are effective, non-habit forming and have no known side-effects.
The Product *(Delivery System)*

*R2MDI*

as a delivery system
Business Objective

*R2’s* mission and objective is to challenge the use of fluticasone propionate/salmeterol xinafoate, budesonide/formoterol, albuterol/salbutamol, budesonide and fluticasone as the preferred medical treatments for asthmatic patients with an innovative *R2* metered dose inhaler containing a proprietary formulation discovered from derivatives of cannabis, manifesting no known side effects.
Project Partnerships

*R2* has developed partnerships with:

- Research physician; Rohit Katial, MD
- Katherine Sanner, Executive Director of Research
- National Jewish Health® to administer the “Study”
- Rocky Mountain Poison and Drug Center of Colorado; a participant in our study
- Marijuana Cultivation Facility and Infused Laboratory (“MIP”;) responsible for production of our proprietary cannabis formulations
- OEM contracted facility(s) to manufacture R2’s proprietary MDI products under *R2* specifications.
Investment Partnership

• R2’s study, R1-V56, will be available for review to our chosen investment partner(s) as well as our expenditure categories and itemized budget proposal, estimated at $1.3M - $1.5M respectfully for costs associated with product research and development, the NJH/R2 one year study, and the manufacturing and retail sale of the Product(s).

• Our chosen investment partner(s) will have access to all testing results and samples of our R2 MDI after execution by both parties of R2’s Non-Disclosure and Material Transfer Agreement.

• The chosen investment partner(s) will be responsible for all costs associated with the budget proposal.

• The R2 MDI, formulations, extractions, and proprietary knowhow will be owned by both parties once a partnership agreement is executed however the United States Provisional / Utility patent application and PCT applications will remain as intellectual property owned solely by Robert L. Senter.
The Study

Study, R1-V56, is to be funded by R2 Innovations, LLC and conducted by National Jewish Health, the leading respiratory hospital in the nation for over 116 years. The purpose of the study is to determine the effects of proprietary cannabis derivatives and formulations developed by R2 Innovations, LLC on bronchial hyper reactivity (BHR) and lung function in patients living in Colorado with asthma.
About R2’s Research Physician

Rohit Katial, MD, FAAAAI, FACP

• Professor of Medicine, National Jewish Health, CO
• Director, Allergy / Immunology – Adult Program
• Director, Weinberg Clinical Research Unit
• Director, Allergy / Immunology Clinical Service
• America’s Top Doctors 2013
• Castle Connolly Medical, Ltd.
• 5280 Top Doctors 2014 (4\textsuperscript{th} year)
• Best Doctors in America\textsuperscript{®} List / Best Doctor’s, Inc.
About Previous Studies

Previous studies and most recently a study Presented to the Colorado State Board of Health, the Colorado Department of Revenue, and the Colorado General Assembly, dated Friday, January 30, 2015 by The Retail Marijuana Public Health Advisory Committee pursuant to C.R.S. 25-1.5-110 (2014);
Confirmed Conclusions

1. Found SUBSTANTIAL evidence that marijuana use (inhaled or digested) results in immediate short-term improvement of lung airflow. [8-10]

2. One-time marijuana use (inhaled or digested) is strongly associated with immediate, short-term (1 to 6 hours) improved airflow in the lungs of healthy marijuana users and asthmatics.
Sources


Project Time Line – To Date

1. R2 Study, R1-V56, approved by National Jewish Health June, 2015
2. Study R1-V56 Budget and R2 expenditures completed and approved July, 2015
3. Intellectual property – Patent information filing(s) August/September 2015
4. NJH, Memorandum of Understanding Agreement executed with R2 August, 2015
5. RMPDC, Memorandum of Understanding Agreement executed with R2 August, 2015
6. Begin Marketing Presentations to potential investor(s) partners, December 2015
7. Investor(s) on board / partnership agreement(s) executed, funding complete, February 2016
8. R2 MDI prototype inhaler samples completed, February / March 2016
9. Study and product development begins April 2016
Robert L. Senter

An industry leading medical and surgical sales specialist since 1980 with a focus on intellectual property and product development for various medical and high-tech industries, including anti-static, and anti-microbial products for the medical, textile, military, aerospace and sports industries.

Mr. Senter has focused his efforts on cannabis derived alternative medicines and formulations for the treatment of Asthma. Once completed Mr. Senter will direct his efforts toward a cannabis derived product(s) for the treatment of COPD and Emphysema.
Summary

**R2 Innovations** seeks to align with an investor partner(s) who will support the projects clinical trials and product development through its completion.

**It is our mission** to place an R2, proprietary cannabis derivative / formulation “on the shelf” six to nine months from completion of the study, utilizing R2’s proprietary, metered dose inhaler and delivery system.

**US Patent protected product(s)** will challenge the multiple, adverse side effects of the primary medicines prescribed for asthmatic patients.

**As an exit strategy,** R2 has chosen to complete product clinical testing and establish manufacturing protocols prior to approaching global pharmaceutical leaders, specializing in respiratory therapy medications.

**After completion** of the initial asthmatic focused product(s), R2 will pursue products for patients suffering from COPD and emphysema, which will parallel similar testing and protocols established in our initial asthma studies and trials.
Thank You

R2 Innovations, LLC
A Colorado Limited Liability Company
82 Marland Road South
Colorado Springs, Colorado 80906
T: 303-808-1750
E: RLS744@Gmail.com
W: R2Innovations.com